CBD Oil for Sleep and ADHD: How CBD Addresses Delayed Circadian Phase, Dopaminergic Hyperarousal, Racing Thoughts at Bedtime, Stimulant-Rebound Insomnia, and the ADHD–Sleep Bidirectional Cycle
By PureCraft Editorial Team | PureCraft CBD | Updated October 2026
Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent neurodevelopmental conditions associated with sleep disruption: 73–78% of adults with ADHD report clinically significant sleep difficulties, a prevalence far exceeding what is observed in the general adult population (approximately 30%). Yet the mechanisms by which ADHD disrupts sleep are not the same as those operating in anxiety-driven insomnia, depression-driven insomnia, or pain-driven insomnia — and understanding what makes ADHD-associated sleep disruption neurobiologically distinct is essential for understanding why CBD oil's specific mechanisms are relevant to it. The primary and most distinctive feature of ADHD-associated sleep disruption is a delayed circadian phase: the ADHD brain's internal clock runs biologically later than the social clock that dictates work, school, and family schedules. Adults with ADHD have later dim-light melatonin onset (DLMO — the gold-standard circadian phase marker) averaging 1.5–2 hours later than neurotypical controls; they have a later cortisol awakening response; they have reduced morning alertness and peak cognitive performance shifted to late afternoon and evening; and they display the evening preference (chronotype) pattern that is the behavioral expression of a biologically later circadian rhythm. This delayed circadian phase means that when the ADHD adult attempts to sleep at a socially normative 10–11 PM, their biological clock is signaling wakefulness — melatonin onset may not occur until midnight or 1 AM, and the sleep pressure-to-arousal ratio has not tipped sufficiently toward sleep for the brain to disengage. Sleep onset at 1–2 AM followed by a forced 6–7 AM awakening for work or school produces the chronic sleep deprivation that then worsens every dimension of ADHD symptomatology during the day.
Beyond the circadian phase delay, ADHD contributes two additional and largely independent sleep-disruption mechanisms: dopaminergic and noradrenergic hyperarousal that maintains wakefulness through the same neural pathways that the disorder's executive function deficit engages, and the bedtime cognitive hyperactivation — racing thoughts, hyperfocus-at-bedtime, mind-racing through unfinished mental loops — that is the most subjectively prominent and most frequently reported ADHD sleep complaint. These three mechanisms (circadian delay, dopaminergic/NE hyperarousal, bedtime cognitive hyperactivation) operate simultaneously and synergistically: an ADHD adult attempting sleep at 10 PM is fighting a biological clock that says midnight, a dopaminergic arousal system that is still activated from the day's activities, and a mind that has shifted into the hyperfocused engagement that the quiet, undistracted pre-sleep environment paradoxically enables. Stimulant medications (methylphenidate, amphetamine salts) add a fourth mechanism for medicated ADHD adults: stimulant rebound insomnia from the late-afternoon or evening stimulant dose wearing off, or from stimulant doses that extend wakefulness past the intended coverage window.
ADHD Medications and CBD Oil: Key Interactions
Methylphenidate (Ritalin, Concerta, Focalin — CYP2D6 minor; primarily non-CYP esterase metabolism): First-line ADHD pharmacotherapy. Methylphenidate is primarily metabolized by carboxylesterases (CES1) rather than CYP enzymes — CBD's CYP enzyme inhibition does not significantly affect methylphenidate plasma levels. The interaction is primarily pharmacodynamic rather than pharmacokinetic: CBD's adenosine elevation and ANS parasympathetic promotion at bedtime directly counteract methylphenidate's dopaminergic/noradrenergic arousal — a mechanistically rational and clinically useful combination for stimulant-rebound insomnia. No significant CYP interaction reported; physician disclosure is still appropriate given the ADHD context and polypharmacy consideration.
Amphetamine salts (Adderall, Vyvanse/lisdexamfetamine — CYP2D6 substrate for amphetamine metabolism): CBD's CYP2D6 inhibition may modestly elevate amphetamine plasma levels or slow amphetamine clearance, potentially extending the duration of stimulant effect and worsening evening insomnia if late doses are taken. More significant: lisdexamfetamine requires conversion to active d-amphetamine by red blood cell CES1 — not a CYP interaction, but CBD's ANS parasympathetic and adenosine mechanisms at bedtime are particularly important for amphetamine-treated ADHD adults who experience pronounced stimulant rebound or extended stimulant effect into the evening. Physician disclosure appropriate; monitor for extended stimulant duration at bedtime when initiating CBD with amphetamine salts.
Atomoxetine (Strattera — CYP2D6 substrate; NE reuptake inhibitor, non-stimulant): CBD's CYP2D6 inhibition may significantly elevate atomoxetine plasma levels — atomoxetine is a CYP2D6-sensitive substrate where CYP2D6 poor metabolizer status produces substantially elevated plasma levels and increased side effects (elevated BP, HR, GI effects, insomnia). CBD's CYP2D6 inhibition essentially converts an extensive metabolizer to a poor metabolizer phenotype for atomoxetine metabolism. Physician disclosure required before combining CBD with atomoxetine; monitor for elevated atomoxetine side effects (cardiovascular effects particularly).
Guanfacine / clonidine (alpha-2 agonists — CYP3A4 substrates; commonly prescribed for ADHD sleep in children/adolescents): CBD's CYP3A4 inhibition may elevate guanfacine and clonidine plasma levels, increasing their blood pressure-lowering and sedative effects. Guanfacine/clonidine are alpha-2 agonists that are sometimes specifically prescribed for ADHD-associated insomnia due to their sedating properties — CBD's CYP3A4 inhibition elevating their levels could enhance or over-extend their sedative and hypotensive effects. Physician disclosure required; monitor for morning sedation carryover and orthostatic hypotension at elevated guanfacine/clonidine levels.
Bupropion (CYP2D6 — sometimes used off-label for adult ADHD): CBD's CYP2D6 inhibition may significantly elevate bupropion plasma levels — dose-dependent seizure risk at elevated levels. Physician disclosure mandatory before combining CBD with bupropion for ADHD or any indication. See also P11-195 for the full bupropion interaction description.
How ADHD Disrupts Sleep: Five Core Mechanisms
1. Delayed Circadian Phase: The ADHD Biological Clock Runs Late
The relationship between ADHD and delayed circadian phase is one of the most robustly replicated findings in ADHD sleep research: multiple studies using dim-light melatonin onset (DLMO) — the gold-standard objective circadian phase marker measured by salivary melatonin collection in dim-light conditions — have demonstrated that adults with ADHD have DLMO averaging 1.5–2 hours later than age- and sex-matched neurotypical controls. This is not a secondary consequence of poor sleep hygiene or inadequate light exposure (though both are relevant factors); it reflects a primary neurobiological difference in the ADHD circadian system. The mechanism: dopamine plays a central role in circadian clock gene expression and in light-signal transduction from the retina to the suprachiasmatic nucleus (SCN) — the master circadian pacemaker. The dopaminergic dysregulation of ADHD (reduced dopamine transporter function, altered D1/D4 receptor signaling in the prefrontal cortex and striatum) appears to affect circadian timing through dopaminergic input to the SCN, the retinal dopaminergic interneurons that modulate light-to-SCN signaling, and the melatonin-synthesis regulation pathways that dopamine modulates via dopamine D2 receptors on pineal cells. The result: the ADHD circadian clock intrinsically prefers a later sleep phase — the biological circadian cycle (period of approximately 24 hours, entrained to local time by light) runs shifted later, so melatonin doesn't rise until midnight or beyond and the biological drive for sleep onset is not present at 10 PM when social schedules demand it. Delayed sleep phase syndrome (DSPS) — a formal circadian rhythm sleep disorder — has a substantially elevated prevalence in ADHD adults (estimates range from 20–50% of ADHD adults meeting criteria for DSPS), supporting the circadian-ADHD relationship. The consequences of forced early wake-up against a late circadian phase: chronic social jetlag (the difference between biological sleep timing and social schedule timing), producing the same cognitive impairment, mood dysregulation, and metabolic disruption as transmeridian jet lag — but experienced every day throughout the week, with partial weekend recovery (sleeping in on weekends to biological wake time) that resets the clock in the wrong direction for Monday morning.
2. Dopaminergic and Noradrenergic Hyperarousal
The dopaminergic and noradrenergic dysregulation that underlies ADHD's executive function deficit and attentional instability also maintains a state of heightened cortical arousal — particularly in the default mode network (DMN) and frontoparietal attention networks — that is the neurobiological substrate of the "mind that won't turn off" that ADHD adults report at bedtime. In the neurotypical brain, the transition from wakefulness to sleep involves deactivation of the DMN (the resting-state network associated with self-referential thought, mental time travel, and internal thought generation) and of the prefrontal executive network — cortical activity decreases, EEG decelerates from the beta/alpha of wakefulness toward the theta/delta of sleep onset. In ADHD, DMN deactivation during attempted cognitive rest is impaired (a robust neuroimaging finding in ADHD: the DMN fails to deactivate appropriately during externally directed tasks, and by extension during sleep-onset attempts at mental quieting). The dopaminergic mechanism: dopamine in the prefrontal cortex via D1 receptors modulates the signal-to-noise ratio of neural networks — insufficient dopaminergic tone in PFC produces noisy, poorly regulated network activity rather than the focused deactivation that sleep onset requires. Noradrenergic hyperactivation: locus coeruleus NE output in ADHD is dysregulated (the same LC-NE system that atomoxetine and strattera target) — elevated NE in the cortex and arousal systems maintains waking alertness and prevents the reduction of arousal that N1/N2 sleep onset requires. The bedtime cortical hyperactivity that results is neurologically measurable: ADHD adults have significantly elevated qEEG beta power (high-frequency waking-associated cortical activity) during pre-sleep quiet wakefulness compared to controls — their brains are neurologically more "awake" at bedtime than neurotypical brains attempting sleep at the same time.
3. Bedtime Cognitive Hyperactivation: Racing Thoughts, Hyperfocus, and Mental Loops
Bedtime cognitive hyperactivation is the most subjectively prominent and most frequently reported ADHD sleep complaint — the experience of lying down to sleep and having the mind accelerate rather than decelerate: racing through unfinished thoughts from the day, hyperfocusing on a topic or problem that seemed unimportant during the distracted daytime, replaying conversations, generating creative ideas, planning future scenarios, or cycling through unresolved mental to-do items that the day's activity had kept at bay. This bedtime cognitive surge is not simply anxiety-driven worry (though anxiety is commonly comorbid with ADHD and contributes its own cognitive arousal); it is a distinctive ADHD phenomenon driven by the removal of external environmental stimulation. During the day, external stimuli (tasks, screens, conversations, sensory input) provide the orienting cues that the ADHD attentional system requires to maintain focus; the pre-sleep environment removes these external orienting cues, and the ADHD brain — without the external scaffolding that structured its daytime attention — generates its own internal stimulation in the form of the racing thought content. This is the same mechanism underlying ADHD hyperfocus (the paradoxical intense concentration that ADHD adults demonstrate on intrinsically engaging activities) — the bedtime pre-sleep quiet becomes intrinsically engaging for the ADHD default mode network precisely because it removes the environmental competition and allows uninterrupted internal thought generation. The neurobiological driver: the DMN hyperactivation and poor default-mode-to-task-network switching of ADHD means the brain at bedtime is in a state of heightened internal thought generation — the exact opposite of the neural state that sleep onset requires. Unlike anxiety-driven cognitive arousal (which has an emotional threat valence — worry about negative future outcomes), ADHD bedtime cognitive hyperactivation may be emotionally neutral or even positively valenced (creative ideas, interesting thoughts, planning enjoyable future activities) — making it harder for the ADHD adult to resist engaging with the mental content, since it doesn't feel distressing, just compelling.
4. Stimulant-Rebound Insomnia and Medication Timing
For the large proportion of ADHD adults who take stimulant medications (methylphenidate or amphetamine-based formulations), a fourth sleep-disruption mechanism operates: stimulant-rebound insomnia and stimulant dose-timing effects. Stimulant medications work by increasing synaptic dopamine and norepinephrine (methylphenidate through DAT/NET reuptake inhibition; amphetamines through DAT/NET efflux and reuptake inhibition combined), directly engaging the same dopaminergic and noradrenergic systems that ADHD's baseline dysregulation produces. Extended-release formulations (Concerta, Vyvanse, Adderall XR) are specifically designed to provide coverage through the work and school day — but their extended duration means that an extended-release dose taken at 8 AM may still have pharmacologically active levels at 6–8 PM, maintaining dopaminergic/noradrenergic arousal that directly opposes the bedtime wind-down that sleep requires. Stimulant rebound — the paradoxical increase in behavioral activation and emotional reactivity that some patients experience as the stimulant dose wears off in the late afternoon or evening — is a distinct phenomenon from extended stimulant duration: the abrupt decline in dopaminergic support as the drug clears can produce a rebound hyperactivity, irritability, and difficulty regulating arousal that is more disruptive to sleep onset than the stimulant's peak effect. The clinical challenge: the same stimulant dose that is necessary and appropriate for daytime ADHD management may be incompatible with an appropriate bedtime for circadian-delayed ADHD adults. The delayed ADHD circadian phase means the patient's intended sleep time is already biologically premature; combined with the stimulant's arousal-maintaining effect extending into the evening, the gap between biological sleep readiness and the social/environmental pressure to sleep becomes even wider. CBD's adenosine elevation and ANS parasympathetic promotion at bedtime provide a mechanistic counterweight to the residual stimulant arousal — without interfering with the stimulant's daytime efficacy, since CBD is taken in the evening when the stimulant's peak effect has passed.
5. Restless Sleep, Frequent Arousals, and the ADHD–Sleep Bidirectional Cycle
Beyond the difficulty falling asleep, ADHD-associated sleep disruption extends into the sleep period itself: ADHD adults report significantly higher rates of restless sleep, frequent nocturnal arousals, parasomnias (sleepwalking, sleep talking — associated with the dopaminergic dysregulation of ADHD in some studies), and non-restorative sleep despite adequate sleep duration (a subjective experience that the sleep "doesn't feel like it did anything" — consistent with reduced N3 quality in some polysomnographic ADHD studies). The bidirectional relationship closes the cycle: sleep deprivation from ADHD-driven insomnia worsens every dimension of ADHD symptomatology. The prefrontal cortex — the primary neural substrate of the executive function deficits that define ADHD — is the brain region most sensitive to sleep deprivation in terms of functional impairment; even one night of partial sleep deprivation significantly impairs working memory, sustained attention, inhibitory control, and cognitive flexibility — the exact executive functions that ADHD already compromises. Sleep-deprived ADHD adults have worse inattention, worse impulse control, and worse emotional dysregulation than their (already impaired) rested state — creating a vicious cycle where poor sleep worsens ADHD, which worsens hyperarousal and delayed phase, which worsens sleep. The dopaminergic depletion from sleep deprivation (sleep is required for dopamine receptor recovery and dopamine precursor synthesis) directly worsens the dopaminergic deficit that is the neurobiological core of ADHD — making sleep not merely a lifestyle consideration but a direct neurochemical requirement for ADHD management. Stimulant medications are consistently less effective on days following poor sleep, and many ADHD adults report that adequate sleep is more important for their ADHD management than stimulant dose optimization — a clinical observation consistent with the neurobiological centrality of sleep to dopaminergic function.
ADHD–Insomnia Mechanism Summary
| ADHD Mechanism | Sleep Disruption Produced | CBD Mechanism Engaged |
|---|---|---|
| Delayed circadian phase (dopaminergic SCN modulation; DLMO 1.5–2 hours later than controls) | Biologically correct sleep onset at midnight–1 AM while social schedule demands 6–7 AM awakening; melatonin not rising at 10–11 PM social bedtime; no biological sleep pressure at intended sleep time; chronic social jetlag producing cumulative sleep deprivation; weekend sleep extension resetting clock further toward late phase (social jetlag worsening over week); morning sleep inertia and cognitive dysfunction from forced early awakening against circadian phase | CBD's adenosine elevation (FAAH/ENT1 inhibition) increases homeostatic sleep pressure (Process S) that complements the circadian drive (Process C) — when the circadian drive is delayed and insufficient at the intended sleep time, elevated adenosine sleep pressure partially compensates, tipping the arousal-sleep balance toward sleep at an earlier clock time than the delayed circadian phase would otherwise allow; HPA normalization reduces evening cortisol that suppresses melatonin, potentially allowing whatever melatonin secretion is available at the delayed DLMO time to be expressed earlier by reducing cortisol-melatonin antagonism; ANS parasympathetic promotion produces the physiological deceleration (reduced HR, reduced cortical activation) that partially mimics circadian wind-down cues at the intended sleep time |
| Dopaminergic and noradrenergic hyperarousal (DMN hyperactivation; elevated pre-sleep beta EEG) | Elevated cortical arousal at bedtime (measurable as elevated qEEG beta power during pre-sleep wakefulness); DMN failure to deactivate during attempted cognitive quieting; noradrenergic LC arousal maintaining vigilance past intended sleep time; extended sleep-onset latency (typically 45–90+ minutes in ADHD adults); daytime cognitive impairment from insufficient sleep reinforcing ADHD attentional deficit; medication decisions complicated by arousal-sedation balance | Adenosine A1 receptor activation (from FAAH/ENT1-mediated adenosine elevation) reduces excitatory glutamate release in cortex and basal forebrain — directly counteracting the dopaminergic cortical hyperactivation of ADHD bedtime state; ANS parasympathetic promotion (HRV improvement, reduced sympathetic arousal) reduces the noradrenergic arousal component; FAAH inhibition elevates anandamide → CB1 activation in basal forebrain arousal systems → reduced histaminergic and cholinergic wakefulness tone; no dopamine receptor interaction (CBD does not directly engage DAT or D1/D2) — meaning CBD reduces the arousal consequences of ADHD dopaminergic dysregulation without altering the dopaminergic system that stimulant medications manage during the day |
| Bedtime cognitive hyperactivation (racing thoughts, hyperfocus, DMN-driven mental loops) | 30–120+ minute sleep-onset latency from internally generated thought engagement at bedtime; hyperfocus on interesting or unfinished mental content in the pre-sleep undistracted environment; difficulty disengaging from compelling thought content that is subjectively not distressing (neutral or positive — making voluntary disengagement harder than with anxiety-driven worry); executive function failure to implement intended sleep preparation behaviors; impaired impulse control at bedtime (screen use extension, late-night activities) further delaying sleep onset; worsening circadian delay from light exposure during the cognitive hyperactivation period | Adenosine elevation reduces cortical excitability that sustains the DMN hyperactivation driving racing thoughts — not by suppressing thought (GABAergic sedation) but by reducing the neuronal excitability that makes thought generation effortless; ANS parasympathetic shift produces the physiological deceleration that cues the brain toward winding down; 5-HT1A modulation (shared with anxiety mechanism) reduces the affective engagement with thought content that makes mental loops compelling; HPA cortisol attenuation reduces the cortisol-driven cortical arousal that amplifies the subjective urgency of the racing thought content; the combination produces gradual cortical "cooling" that makes disengagement from the mental content progressively easier over the 60–90 minutes following sublingual CBD administration |
| Stimulant-rebound insomnia (methylphenidate/amphetamine evening residual or rebound effect) | Extended-release stimulant residual dopaminergic/NE arousal at intended bedtime; stimulant rebound hyperactivity and emotional dysregulation in late afternoon; dose-timing conflict between daytime efficacy requirements and evening sleep requirements; difficulty calibrating extended-release dose for adequate day coverage without evening insomnia; weekend stimulant holiday sleep disruption (rebound hypersomnia when stimulants withheld); inadequate stimulant dosing to avoid insomnia producing daytime ADHD under-treatment | CBD's adenosine and ANS parasympathetic mechanisms at bedtime provide a direct pharmacodynamic counterbalance to residual stimulant dopaminergic/NE arousal — adenosine opposes the dopamine arousal signal at the level of cortical excitability; ANS parasympathetic shift opposes the sympathetic activation of residual stimulant NE; the combination works at the bedtime hour when stimulants are intended to have passed peak effect, providing a "landing pad" of reduced cortical and autonomic arousal that allows sleep onset despite residual stimulant activity; methylphenidate's primary non-CYP metabolism means CBD's enzyme inhibition does not extend stimulant duration, preserving daytime efficacy while addressing evening arousal |
| ADHD–sleep bidirectional cycle (sleep deprivation worsening PFC executive function and dopaminergic deficit) | Sleep deprivation → PFC executive function impairment (most sleep-sensitive brain region) → worse inattention, impulse control, working memory → worse ADHD all day; sleep deprivation → dopaminergic depletion → worsened ADHD core deficit → worse behavioral hyperarousal at bedtime; reduced stimulant medication effectiveness on sleep-deprived days; emotional dysregulation worsening from sleep deprivation → worse evening behavioral regulation contributing to circadian phase delay; cumulative cognitive debt from years of social jetlag producing chronic underperformance beyond medication management alone | CBD's progressive improvement in sleep-onset latency over 4–8 weeks incrementally reduces the chronic sleep deprivation that perpetuates the cycle; N3 slow-wave promotion (adenosine) improves sleep quality within the available sleep window; reduced sleep-onset latency from earlier bedtime transition (earlier circadian sleep-pressure tipping point from adenosine) expands total sleep time; better daytime dopaminergic function from improved sleep → reduced bedtime hyperarousal → improved next-night sleep onset — positive cycle replacing the negative one; PFC executive function improvement from adequate sleep supports ADHD behavioral management strategies (sleep hygiene implementation, screen use self-regulation at bedtime) that ADHD adults find difficult to sustain when sleep-deprived |
The Adenosine Mechanism: Why It Is Uniquely Relevant for ADHD Sleep
Among CBD oil's several sleep-relevant mechanisms, the adenosine elevation pathway (FAAH inhibition increasing anandamide → endocannabinoid-mediated inhibition of equilibrative nucleoside transporter 1 (ENT1) → reduced adenosine clearance → elevated extracellular adenosine → A1 and A2A receptor activation) is particularly relevant to ADHD-associated insomnia for reasons that go beyond its general sleep-promoting function. Adenosine's role in ADHD neurobiology is itself an area of active research: adenosine A1 receptors modulate dopamine D1 receptor signaling through direct receptor-receptor interactions (A1-D1 heteromers) in the prefrontal cortex — adenosine A1 activation reduces D1 receptor sensitivity and downstream cAMP signaling. This A1-D1 interaction means adenosine is a direct modulator of the dopaminergic system that ADHD pharmacotherapy (stimulants targeting DAT) engages. During sleep, adenosine accumulation in the prefrontal cortex may support the dopamine receptor recovery and downregulation normalization that sleep provides for the ADHD brain — helping restore dopaminergic sensitivity that the day's cognitive activity depletes. Additionally, adenosine A2A receptors in the striatum and nucleus accumbens modulate dopaminergic reward signaling through A2A-D2 receptor interactions — the same striatal circuits that motivational dysregulation and reward-seeking in ADHD engages. The caffeine connection is particularly illustrative: caffeine — the world's most widely consumed psychoactive substance — produces its arousal-maintaining effects almost entirely through adenosine A1/A2A receptor antagonism. The well-documented fact that ADHD individuals self-medicate with caffeine at significantly higher rates than the general population suggests that the adenosine-dopamine interaction may be specifically relevant to ADHD neurobiology. FAAH/CBD-mediated adenosine elevation, by contrast, promotes the adenosinergic sleep drive that caffeine suppresses — working directly against the mechanism by which ADHD individuals' self-medication worsens their own sleep.
ADHD Sleep Population Profiles
Medicated ADHD Adults: Stimulant Rebound and Evening Arousal
Adults on methylphenidate (Concerta, Ritalin LA, Focalin XR) or amphetamine formulations (Adderall XR, Vyvanse) represent the largest ADHD treatment population and are also the group with the most complex sleep challenge: they need stimulant medication for daytime function, but the stimulant's arousal-maintaining mechanism directly opposes the bedtime wind-down that their already-delayed circadian phase makes difficult. For this group, CBD's most targeted application is as a pharmacodynamic evening counterbalance to residual stimulant activity: the bedtime sublingual oil (taken 60–90 minutes before intended sleep, approximately 3–4 hours after the last stimulant dose) provides adenosine elevation and ANS parasympathetic promotion when the stimulant's primary therapeutic window has passed but residual arousal may remain. Methylphenidate: no significant CYP interaction with CBD; the combination is pharmacodynamically rational with no pharmacokinetic concern. Amphetamine salts: modest CYP2D6 consideration (physician disclosure); CBD's ANS parasympathetic bedtime effect is particularly important for amphetamine-treated adults who experience more pronounced evening arousal rebound. Atomoxetine: CYP2D6 significant interaction (physician disclosure and monitoring for elevated atomoxetine side effects).
Unmedicated/Non-Stimulant ADHD Adults: Circadian Delay and Cognitive Hyperactivation
Adults managing ADHD without stimulant medications — whether by choice, intolerance, contraindication, or late-diagnosis not yet engaged with pharmacotherapy — experience the sleep disruption of ADHD without the stimulant dose-timing complication. For this group, the circadian phase delay and bedtime cognitive hyperactivation are the primary targets. CBD's adenosine mechanism is most important here: elevating homeostatic sleep pressure (Process S) to partially compensate for the insufficient circadian drive (Process C) at the biologically premature social bedtime. The earlier pre-sleep timing recommendation (90 minutes before intended sleep rather than 60 minutes) gives CBD's progressive bedtime physiological calming — ANS parasympathetic shift, cortical excitability reduction from adenosine — the maximum time to build before the sleep attempt. For ADHD adults who have never taken stimulants and are considering whether CBD or stimulants should come first: these are not competing interventions — CBD for sleep support and stimulant pharmacotherapy for daytime ADHD management address different aspects of the disorder. Sleep improvement from CBD may itself improve daytime ADHD symptoms (the bidirectional cycle working in the positive direction), but adequate daytime ADHD management remains a separate clinical consideration requiring physician guidance. Atomoxetine (non-stimulant ADHD pharmacotherapy): physician disclosure mandatory for CYP2D6 interaction with CBD.
Dosing CBD Oil for ADHD-Driven Insomnia
ADHD Sleep Protocol: Timing, Stimulant Coordination, and Gradual Phase Advance
Pre-sleep timing (most critical variable for ADHD): 90 minutes before intended sleep — earlier than the standard 60-minute timing recommended for pain or non-circadian insomnia. For ADHD-delayed circadian phase, the intended sleep time is already biologically premature; the earlier CBD pre-dose gives adenosine the maximum lead time to reduce cortical excitability and begin the physiological wind-down before the sleep attempt. For medicated ADHD adults: take CBD approximately 3–4 hours after the last stimulant dose of the day, and 90 minutes before intended sleep — this positions CBD's peak adenosine effect as the stimulant's residual arousal is declining, rather than timing the two peaks to compete directly.
Gradual phase advance strategy (for pronounced circadian delay): For ADHD adults with very late habitual sleep times (natural sleep onset at 1–3 AM), immediate 10 PM sleep attempts with CBD will be insufficient — the circadian drive mismatch is too large for adenosine alone to overcome on the first night. A gradual phase advance approach: take CBD at the natural sleep time for 3–5 nights (midnight or 1 AM), then shift the CBD dose and intended sleep time 15 minutes earlier every 3–4 days, gradually advancing toward the target sleep time over several weeks. This allows the sleep-onset success that builds circadian anchoring while the adenosine mechanism progressively supports earlier sleep pressure. Morning light exposure (outdoor morning light at natural wake time for the target circadian phase) is the single most effective complement to CBD's sleep-pressure approach for circadian phase advance.
Start: 10 mg nanoemulsion broad spectrum oil sublingual, 90 minutes before intended sleep. Titrate 5 mg every 2 weeks. Target: 20–35 mg for ADHD sleep (typically lower effective dose than pain conditions — the primary mechanism is adenosine accumulation rather than TRPV1 desensitization, which requires dose-dependent receptor loading). For pronounced stimulant rebound: slightly higher evening dose (25–30 mg) may be needed to counterbalance the residual stimulant arousal; physician disclosure of the combination allows dose-finding with awareness of the mechanism.
Timeline: Acute adenosine-mediated sleep-latency reduction: some effect within the first 1–2 weeks for many ADHD individuals. Progressive improvement (more consistent earlier sleep onset, reduced racing thoughts at bedtime): 4–6 weeks. Circadian phase normalization (biological shift toward earlier sleep phase): 8–12 weeks with consistent use and complementary morning light practices. Note: CBD does not replace light therapy or chronobiology-based circadian interventions for DSPS — it complements them through the homeostatic sleep pressure (Process S) pathway that light therapy addresses through the circadian (Process C) pathway.
PureCraft Products for ADHD-Driven Insomnia
Foundation: Sublingual Oil for Pre-Sleep Adenosine and ANS Parasympathetic Support
The Nano CBD Broad Spectrum Oil is the essential foundation for ADHD-driven insomnia, taken 90 minutes before intended sleep to maximize the adenosine elevation and ANS parasympathetic promotion lead time before the sleep attempt. For medicated ADHD adults (methylphenidate — no CYP concern; amphetamines — physician disclosure): the sublingual oil's faster onset (30–60 minutes for nanoemulsion) positions peak adenosine effect during the final hour before intended sleep, when the stimulant's therapeutic window has largely passed and residual arousal is the primary obstacle to sleep onset. The earlier pre-sleep timing (90 minutes) is more important for ADHD than for any other condition in this series — the circadian delay means the sleep-onset window requires the longest adenosine preparation time to shift the arousal-sleep balance toward sleep onset before the intended sleep time. Broad spectrum (THC-free) is appropriate for ADHD: THC's CB1 arousal-disrupting effects on REM architecture and the potential for THC to worsen attention and motivation the following day make broad spectrum (CBD-only terpene profile) the appropriate formulation. Start at 10 mg; titrate to 20–30 mg based on sleep-onset response at 2-week intervals.
Sleep Timing and Circadian Support
The Nano CBD CBN D9 Infused Vegan Gummies with Melatonin provides an important complement to the sublingual oil specifically for ADHD's delayed circadian phase. The melatonin component (taken 90 minutes before intended sleep alongside the sublingual oil) directly addresses the DLMO delay that underlies ADHD's circadian phase problem: exogenous low-dose melatonin taken approximately 5 hours before DLMO advances the circadian phase by the chronobiological mechanism of early melatonin supplementation signaling. For ADHD adults whose natural DLMO is midnight: taking low-dose melatonin at 8:30–9 PM (90 minutes before a 10:30 PM intended sleep) provides a phase-advancing melatonin signal at a time when endogenous melatonin has not yet risen — using melatonin's phase-advancing property (taking it before natural DLMO advances the clock; taking it after natural DLMO, as a sedative, does not advance the phase). The CBN component adds mild cannabinoid sedation support; the D9 microdose contributes gentle CB1 sleep promotion. Note: this product is appropriate for ADHD adults not subject to drug testing (melatonin is not tested; D9 THC microdose may flag drug screens) and not on medications with specific D9 interaction concerns. For drug-tested or D9-cautious individuals: sublingual oil + softgel without the melatonin gummy is the appropriate alternative.
Sleep Architecture Quality Within the Available Sleep Window
The Nano CBD Water-Soluble Broad Spectrum Softgels serve a specific function for ADHD-associated sleep disruption that is different from their role in depression (early-morning coverage) or pain (overnight analgesic continuity): the softgel's extended-release profile provides sustained adenosine support and CNS excitability reduction through the early morning light sleep stages when ADHD-associated nocturnal arousals and restless sleep most commonly occur. The ADHD sleep period is not just difficult to initiate — it is also more fragmented and lighter than neurotypical sleep, with more frequent arousals particularly in the N1/N2 lighter sleep stages and with the behavioral activation that characterizes ADHD sometimes emerging in parasomnias. The bedtime softgel's 6–8 hour extended coverage supports sleep continuity through the sleep period, reducing the frequency of arousals that fragment ADHD sleep quality. For ADHD adults who achieve sleep onset reasonably well but report non-restorative, light, or fragmented sleep: the softgel at bedtime addresses the sleep-maintenance dimension of ADHD insomnia that the sublingual oil's shorter duration may not fully cover. Add after establishing the sublingual oil dose (2–4 weeks), beginning at 10 mg.
Frequently Asked Questions About CBD Oil for Sleep and ADHD
Does CBD oil help with ADHD sleep problems?
CBD oil addresses ADHD-associated insomnia through mechanisms that target the specific neurobiological drivers of ADHD's sleep disruption: adenosine elevation (FAAH/ENT1 inhibition) increases homeostatic sleep pressure (Process S) that partially compensates for the insufficient circadian drive at the biologically premature social bedtime; ANS parasympathetic promotion produces the physiological deceleration (reduced HR, reduced cortical arousal) that the ADHD brain resists at bedtime; and 5-HT1A modulation reduces the emotional engagement with racing thought content that sustains bedtime cognitive hyperactivation. The combination addresses all three primary ADHD sleep mechanisms — circadian delay compensation through increased sleep pressure, dopaminergic/NE hyperarousal reduction through adenosine and ANS mechanisms, and bedtime cognitive hyperactivation reduction through adenosine cortical excitability reduction and 5-HT1A modulation. Formal clinical trials of CBD specifically for ADHD-associated insomnia are limited in the current literature, but the mechanistic rationale (adenosine's role in compensating for circadian delay and reducing cortical hyperactivation) and the well-established clinical observation of CBD's sleep-onset benefits in hyperarousal presentations support its application for ADHD sleep. CBD is not a treatment for ADHD itself — it does not improve daytime attention, impulse control, or executive function during the waking day — but better sleep from CBD support may indirectly improve daytime ADHD symptoms through the bidirectional cycle (improved sleep → better PFC executive function → better daytime ADHD management).
Can CBD oil be used with ADHD stimulant medications for sleep?
CBD oil can be used alongside most ADHD stimulant medications for sleep, with the key pharmacological consideration depending on which medication is involved. Methylphenidate (Concerta, Ritalin LA, Focalin XR): primarily metabolized by carboxylesterase enzymes (CES1) rather than CYP enzymes — CBD's CYP enzyme inhibition does not significantly affect methylphenidate plasma levels. The combination is pharmacodynamically rational: CBD's bedtime adenosine elevation and ANS parasympathetic promotion work against the residual methylphenidate arousal without affecting its daytime therapeutic window (CBD is taken in the evening, well after methylphenidate's peak daytime effect). Physician disclosure is appropriate but no significant pharmacokinetic interaction is expected. Amphetamine salts (Adderall XR, Vyvanse): modest CYP2D6 consideration for amphetamine metabolism; physician disclosure before combining. CBD's evening adenosine and parasympathetic mechanisms remain pharmacologically rational for stimulant rebound management. Atomoxetine (Strattera): CYP2D6 significant interaction — CBD inhibition may substantially elevate atomoxetine plasma levels, increasing cardiovascular and GI side effects. Physician disclosure and monitoring required before combining. Guanfacine/clonidine: CYP3A4 interaction elevating sedative and hypotensive effects — physician oversight required. The general principle: CBD's bedtime use for ADHD sleep is targeting a window (evening, 3–4 hours after last stimulant dose) when the stimulant's intended therapeutic effect has largely passed, minimizing the overlap between CBD's sleep-promoting and stimulant's arousal-maintaining effects while providing a pharmacodynamic bridge to sleep onset.
Does CBD oil help with racing thoughts at bedtime in ADHD?
Racing thoughts at bedtime in ADHD are distinct from anxiety-driven racing thoughts: ADHD bedtime cognitive hyperactivation is driven by the default mode network's (DMN) freed engagement in the undistracted pre-sleep environment, generating intrinsically compelling thought content (ideas, plans, creative solutions, unfinished mental loops) rather than the threat-focused worry of anxiety. CBD oil addresses this ADHD-specific bedtime cognitive hyperactivation through the adenosine mechanism: adenosine A1 receptor activation reduces excitatory glutamate in the cortex, gradually lowering the neuronal excitability that makes internal thought generation effortless and compelling at bedtime. The subjective experience: thoughts don't stop abruptly (CBD is not a thought-suppressing sedative), but the ease with which the mind generates and engages with thought content gradually diminishes over the 60–90 minutes following sublingual CBD administration — the mental loops become less self-sustaining, the effort required to set aside a thought decreases, and the transition from active internal thought to the passive mental quieting of pre-sleep becomes less effortful. The ANS parasympathetic component adds a physiological signal: the progressive reduction in heart rate and muscle tension that CBD's ANS promotion produces provides the body-level relaxation cue that the mind can follow toward wind-down. For ADHD adults with comorbid anxiety (approximately 50% of ADHD adults have a comorbid anxiety disorder), CBD's 5-HT1A amygdala desensitization also reduces the anxiety-driven component of bedtime racing thoughts that co-occurs with the ADHD-specific component. The 90-minute pre-sleep timing recommendation for ADHD (earlier than the 60-minute standard for other conditions) allows the adenosine accumulation and ANS shift to be well underway before the sleep attempt begins.
How much CBD oil should I take for ADHD sleep?
CBD oil dosing for ADHD-driven insomnia follows the standard protocol with specific ADHD timing modifications. Start: 10 mg nanoemulsion broad spectrum oil sublingual, 90 minutes before intended sleep (the extended pre-sleep timing is the most important ADHD-specific modification). Titrate: 5 mg every 2 weeks. Target range: 20–30 mg for ADHD sleep — typically lower than the dose needed for chronic pain conditions, since the mechanism (adenosine homeostatic sleep pressure) does not require the dose-dependent receptor loading that TRPV1 desensitization demands. For pronounced stimulant rebound insomnia (marked difficulty falling asleep even hours after the last stimulant dose): target 25–35 mg to provide sufficient adenosine and ANS parasympathetic counterbalance to residual stimulant arousal. For pronounced circadian delay (natural sleep onset typically past 1 AM): consider adding the melatonin gummy (taken 90 minutes before intended sleep alongside the sublingual oil) for the phase-advancing melatonin effect that works alongside CBD's adenosine sleep pressure increase. For sleep-maintenance issues (restless sleep, frequent nocturnal arousals) after sleep-onset latency is improved: add bedtime softgel (10–15 mg alongside the sublingual oil) for extended sleep-period coverage. Minimum evaluation period: 8 weeks for sleep-onset improvement; 10–12 weeks for circadian phase normalization. Do not evaluate during the first 2–3 weeks — the adenosine mechanism builds progressively with consistent nightly dosing.
Does CBD oil affect ADHD symptoms during the day?
CBD oil does not directly treat ADHD symptoms during the day — it is not an attention-enhancing, impulse-control-improving, or executive-function-supporting agent through direct daytime pharmacological action. CBD does not increase dopaminergic or noradrenergic activity (the mechanism of stimulant ADHD treatment) and does not engage the prefrontal D1 receptor signaling that attention regulation requires. The indirect daytime benefit of CBD for ADHD is mediated through sleep improvement: better sleep from CBD support at night → improved PFC executive function during the day → reduced ADHD symptom expression through adequate sleep rather than direct pharmacological ADHD treatment. This indirect pathway is clinically meaningful but should not be overstated. Daytime CBD use for ADHD is not recommended from a mechanism perspective — CBD's adenosine elevation during daytime would add homeostatic sleep pressure at a time when wakefulness and attention are required, potentially reducing daytime alertness in individuals (like ADHD adults) whose attention regulation is already challenged. The appropriate CBD application for ADHD is strictly evening/bedtime (90 minutes before intended sleep), not daytime; morning or midday CBD doses could worsen the daytime attention difficulties that ADHD adults are already managing. For those ADHD adults considering CBD for both sleep and daytime anxiety comorbidity: separate the mechanisms — strictly evening CBD for sleep, and discuss daytime anxiety management (physician-supervised SSRI or non-pharmacological CBT approaches) separately from the sleep-focused CBD use.
Does CBD oil interfere with Adderall or Vyvanse?
CBD oil's interaction with Adderall (amphetamine salts) and Vyvanse (lisdexamfetamine) is primarily pharmacodynamic rather than pharmacokinetic, when CBD is used strictly for evening/bedtime sleep support. Pharmacokinetics: amphetamine metabolism involves CYP2D6 for some metabolic pathways — CBD's CYP2D6 inhibition may modestly affect amphetamine clearance. Lisdexamfetamine is converted to active d-amphetamine by red blood cell CES1 (not CYP-dependent), so the conversion step is not CYP2D6-affected; subsequent amphetamine metabolism does involve CYP2D6 to some degree. The clinical significance of CBD's CYP2D6 effect on amphetamine is likely modest for bedtime CBD doses (lower CBD plasma levels at bedtime hours after daytime amphetamine dosing), but physician disclosure is appropriate. Pharmacodynamics: CBD's bedtime adenosine elevation and ANS parasympathetic promotion work against the residual amphetamine NE/dopamine arousal — this is the intended therapeutic effect for stimulant-rebound insomnia, not an unwanted interaction. CBD does not block the dopaminergic mechanism of amphetamine during the daytime peak effect window; the daytime therapeutic window of Adderall XR (8 AM to 4–6 PM) has largely passed by the time an ADHD adult takes CBD at 8:30–9 PM for a 10:30 PM sleep target. The key message for Adderall/Vyvanse users: disclose CBD use to the prescribing physician before initiating; take CBD strictly in the evening as directed for sleep (not during the day); and do not adjust stimulant doses based on CBD use without physician guidance.
Why do people with ADHD sleep so late?
ADHD adults sleep late primarily because of a biologically delayed circadian phase — not laziness, poor discipline, or simple bad sleep habits. The ADHD brain's circadian clock runs approximately 1.5–2 hours later than the population average, as measured by the gold-standard dim-light melatonin onset (DLMO) assay. This delay is driven by the dopaminergic dysregulation of ADHD — dopamine plays a role in circadian clock gene expression, light-signal transduction from the retina to the suprachiasmatic nucleus (the brain's master circadian clock), and melatonin synthesis regulation through pineal D2 receptors. The practical consequence: the ADHD brain genuinely does not receive the biological sleep-onset signal (rising melatonin, declining body temperature, reduced cortisol) until midnight or later. Attempting to sleep at 10 PM against a biological midnight DLMO is the neurological equivalent of attempting to sleep at 4 PM with a normal circadian phase — the sleep drive is simply not present yet, regardless of how long the person has been awake or how much sleep they need. The evening alertness and productivity that ADHD adults often experience (the "second wind" at 10–11 PM when work finally feels manageable, creative ideas flow more easily, or sustained focus becomes achievable) is a direct expression of the delayed circadian peak alertness phase — the ADHD brain's optimal cognitive performance window is shifted to 8–11 PM when neurotypical brains are winding down. This circadian reality is important for ADHD adults to understand: the late sleep is a neurobiological characteristic of their condition, not a personal failing — and managing it effectively requires understanding the circadian mechanism rather than simply trying harder to sleep earlier through willpower alone.
Is full spectrum or broad spectrum CBD oil better for ADHD sleep?
Broad spectrum CBD oil (THC-free) is recommended for ADHD-associated insomnia rather than full spectrum, for several reasons specific to ADHD neurobiology. THC's acute cognitive effects — impaired working memory, reduced processing speed, potential worsening of attention — are particularly problematic for ADHD: the residual THC cognitive effects the morning after full spectrum use could worsen the executive function deficit that ADHD adults are already managing, particularly in the already-vulnerable morning hours following forced early awakening against a delayed circadian phase. ADHD adults have a significantly elevated risk for cannabis use disorder compared to the general population (the same reward-system dysregulation that drives ADHD's impulsivity contributes to addictive behavior risk), and regular use of THC-containing products carries greater addiction-risk relevance in this population than in neurotypical individuals. THC's effects on REM sleep architecture (suppression at higher doses; possible REM rebound on discontinuation) add complexity to the sleep-architecture changes that ADHD sleep already presents. Broad spectrum CBD provides the adenosine, 5-HT1A, ANS, and HPA mechanisms relevant to ADHD sleep without THC's cognitive, addiction-risk, and REM-complication concerns. For ADHD adults interested in the melatonin gummy (which contains D9 microdose): the distinction between broad spectrum (the foundation oil and softgels) and the melatonin gummy's D9 content is important to understand — the D9 contribution in the melatonin gummy is intended as a minor sleep-initiation support, not a THC-dose sleep medication. Drug testing consideration: D9 at any dose may flag workplace drug screens — avoid the melatonin gummy if drug testing is a concern.
How quickly does CBD oil work for ADHD sleep?
CBD oil's timeline for ADHD sleep improvement has two phases consistent with the broader CBD sleep literature. Acute effect (first 1–2 weeks): many ADHD individuals report a noticeable reduction in sleep-onset latency within the first several nights of consistent bedtime CBD use, reflecting the immediate adenosine elevation and ANS parasympathetic shift that nanoemulsion sublingual CBD produces within 30–60 minutes. The acute effect is variable — some report meaningful sleep-onset improvement within the first week; others require 2–3 weeks to notice consistent benefit. For stimulant-rebound insomnia specifically, the acute adenosine counterbalance to residual stimulant arousal is the mechanism most likely to show early response. Progressive improvement (4–12 weeks): the progressive normalization of HPA cortisol patterns (reducing the evening cortisol that suppresses melatonin at the delayed DLMO time) and the progressive 5-HT1A modulation of the bedtime cognitive hyperactivation operate on a 4–8 week timeline. Circadian phase advance (gradual shift toward earlier sleep onset): 8–12 weeks of consistent use combined with complementary morning light practices. A realistic expectation: sleep-onset latency improvement within 2–4 weeks; reduced racing-thought intensity at bedtime within 4–6 weeks; more consistent sleep-onset timing and reduced night-to-night variability (a hallmark ADHD sleep characteristic — wildly inconsistent sleep timing from night to night) within 8–10 weeks. ADHD's intrinsic executive function challenges make consistent nightly dosing harder to maintain than for other conditions — habit-stacking the CBD dose with an existing bedtime routine anchor (brushing teeth, taking off glasses, charging phone) improves adherence and therefore outcome.
What is the best CBD oil for ADHD sleep?
The best CBD oil for ADHD sleep prioritizes: nanoemulsion format for consistent bioavailability (variable-absorption standard CBD oil produces the inconsistent nightly effects that are particularly problematic for the already-inconsistent ADHD sleep pattern — reliable pharmacokinetics matter more for ADHD than for most other sleep presentations); broad spectrum (THC-free) for the cognitive and addiction-risk reasons described above; sublingual delivery for the fastest onset relevant to the 90-minute pre-sleep timing window; and product consistency from third-party tested manufacturing. The Nano CBD Broad Spectrum Oil (sublingual, 90 minutes before sleep) is the foundation. For circadian delay: add the Nano CBD CBN D9 Infused Vegan Gummies with Melatonin (for the phase-advancing melatonin component alongside CBD's adenosine sleep-pressure increase — if drug testing is not a concern and individual medication list permits). For sleep fragmentation or maintenance issues: add the Nano CBD Water-Soluble Broad Spectrum Softgels at bedtime for extended nocturnal coverage. The ADHD adult's executive function challenge in implementing the protocol consistently is real — start with the single sublingual oil product only and establish the habit before adding additional products. One product done consistently is more effective than three products done inconsistently.
Related Articles
- → CBD Oil for Sleep and Anxiety: How CBD Addresses Anxiety-Driven Hyperarousal, Amygdala Reactivity, and the Anxiety–Insomnia Cycle
- → CBD Oil for Sleep and Depression: REM Excess, HPA Glucocorticoid Resistance, and Early Morning Awakening
- → CBD Oil for Shift Work Sleep Disorder: Circadian Disruption, Two-Process Sleep Model, and Schedule-Anchored Timing
- → CBD Oil for Deep Sleep: N3 Slow-Wave Sleep, Adenosine, and Restorative Sleep Architecture
- → CBD Oil for Sleep: How CBD's Mechanisms Address the Biology of Insomnia
References
- Blessing EM, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825–836. PMID: 26341731
- Shannon S, et al. Cannabidiol in Anxiety and Sleep: A Large Case Series. Perm J. 2019;23:18–041. PMID: 30624194
- Russo EB. Cannabinoids in the management of difficult to treat pain. Ther Clin Risk Manag. 2016;4(1):245–259. PMID: 28861491
- Crippa JA, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder. J Psychopharmacol. 2011;25(1):121–130. PMID: 20829306
- Corroon J, Phillips JA. A Cross-Sectional Study of Cannabidiol Users. Cannabis Cannabinoid Res. 2018;3(1):152–161. PMID: 30014049
- Capano A, et al. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients. Postgrad Med. 2020;132(1):56–61. PMID: 31711352
Medical Disclaimer
This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent attention deficit hyperactivity disorder (ADHD), attention deficit disorder (ADD), delayed sleep phase syndrome, insomnia, or any other neurodevelopmental or medical condition. CBD oil is not a treatment for ADHD and does not replace physician-prescribed ADHD pharmacotherapy or behavioral interventions. ADHD is a neurodevelopmental condition that may require professional evaluation and physician-supervised pharmacotherapy for effective management. Individuals taking ADHD medications — including methylphenidate, amphetamine salts, atomoxetine, guanfacine, clonidine, or bupropion — must disclose CBD use to their prescribing physician before initiating, due to potential pharmacokinetic and pharmacodynamic interactions. Atomoxetine (CYP2D6) and guanfacine/clonidine (CYP3A4) carry the most significant pharmacokinetic interaction concerns with CBD. The D9-containing melatonin gummy product may produce positive results on drug screens; individuals subject to workplace or other drug testing should use only THC-free broad spectrum products. The statements in this article have not been evaluated by the Food and Drug Administration. Individual responses to CBD vary. This article does not constitute medical advice — consult your physician before making changes to your ADHD treatment or sleep regimen.
